Trial Profile
A Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Moderate-to-Severe Uncontrolled Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2022
Price :
$35
*
At a glance
- Drugs Itolizumab (Primary)
- Indications Asthma
- Focus Adverse reactions; Proof of concept
- Acronyms EQUIP
- Sponsors Equillium
- 20 Jan 2022 Status changed from recruiting to completed.
- 04 Jan 2022 Results (n=18) published in the Equillium media release.
- 10 Nov 2021 According to an Equillium media release, topline data in uncontrolled asthma expected in Q4 2021.